Pancreatic Cancer Therapeutics and Diagnostics Market - Growth, Trends, and Forecast (2019 - 2024)
|出版商||Mordor Intelligence LLP||商品編碼||353881|
|出版日期||內容資訊||英文 112 Pages
|胰臟癌症的治療及診斷的全球市場:成長，趨勢，及預測(2019年∼2024年) Pancreatic Cancer Therapeutics and Diagnostics Market - Growth, Trends, and Forecast (2019 - 2024)|
|出版日期: 2019年03月01日||內容資訊: 英文 112 Pages||
Pancreatic cancer is the 12th most common cancer in the world. The estimated five-year prevalence of people living with pancreatic cancer is 4.1 per 100,000, globally. This cancer is almost always fatal and is the seventh most common cause of death from cancer. Pancreatic cancer is closely related to body fat and high BMI, thereby being more prevalent in the developed countries. A report by the Centers for Disease Control and Prevention (CDC) estimated that pancreatic cancer resulted in the death of about 330,000 people in 2012 in the United States, which was around 4% of all deaths in the country. Estimates of the American Cancer Society suggested that in the United States alone, nearly 53,070 new cases of pancreatic cancer were recorded in 2016 and 41,780 deaths in the country were attributed to the same. In Europe, nearly 104,000 new cases of pancreatic cancer were estimated to be diagnosed in 2012. The extensive threat of pancreatic cancer is a major opportunity for companies to capitalize on the market through the expansion of product portfolios and market penetration. The high patient pool and increasing trends of the same are expected to propel the growth of the market.
Pancreatic cancer occurs when there is an uncontrollable growth of cells in the pancreas. Pancreatic cancer is categorized as exocrine and endocrine, based on the cells affected by cancer. Exocrine cells in pancreas create pancreatic enzymes. When cancer manifests in these cells, it is referred to as exocrine pancreatic cancer. Endocrine cells are a small cluster of cells and also called 'islets of Langerhans'. These cells create hormones, such as insulin and glucagon, releasing them into the blood flow. Cancer in these cells is called endocrine pancreatic cancer.
Targeted Therapy Segment is expected to exhibit fastest growth rate over the forecast period
Pancreatic cancer therapeutics is basically classified into chemotherapy, surgery, targeted therapy, and others. The targeted therapy segment is expected to witness the fastest growth rate over the forecast period owing to the higher efficacy, increasing rate of innovations, and speedy drug approvals. Targeted therapy can be referred to as the treatment with the use of drugs or other biochemical substances in order to identify and target specific cancerous cells with no or minimal harm to the healthy cells surrounding the cancer cell. For instance, Tyrosine kinase inhibitors (TKIs) are a type of targeted therapy drugs that block the activity of cell growth in the cancerous cells. Erlotinib is an example of TKI used in targeted therapy for the treatment of pancreatic cancer.
North America dominated the overall market and is expected to retain its dominance
North America dominated the pancreatic cancer therapeutics and diagnostics market. In the United States, the average lifetime risk of pancreatic cancer for both men and women is about 1 in 65 (1.5%). Pancreatic cancer accounts for about 3% of all cancers in the United States and about 7% of cancer deaths. The Pancreatic Cancer Action Network predicts pancreatic cancer to become the second leading cause of cancer-related deaths in the United States, by 2020. With promising drugs in the pipeline, the US pancreatic cancer therapeutics and diagnostics market is expected to witness lucrative growth during the forecast period. The high healthcare spending and state-of-the-art healthcare facilities in the United States are expected to promote the growth of the market, indirectly. The country is also a hub for high-end R&D activities, which are anticipated to have a positive impact on the novel product developments and clinical trials.
The presence of major market players, such as Amgen, Eli Lilly, F. Hoffmann La-Roche, Novartis, and Pfizer, among others is intensifying the competition. The market players are adopting strategies, such as rising R&D investments, mergers, acquisitions, and product innovations in order to sustain the increasing market rivalry.